Assignee
GLENMARK PHARMACEUTICALS SA
CH·45 granted patents·45 pending applications·219 citations·filing 2004–2022
Top patents by PatentIndex Score
90 records- 0196US9493563B2Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Nov 15, 2016·47 cites·3 claims
- 0294US9683053B2Hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Jun 20, 2017·38 cites·21 claims
- 0392US9290576B2Antibodies that bind to TL1A and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Mar 22, 2016·22 cites·51 claims
- 0487US9855229B2Treatment of respiratory disorders using ROR-gamma inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Jan 2, 2018·12 cites·5 claims
- 0586US9096545B2Triazolone compounds as mPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Aug 4, 2015·7 cites·36 claims
- 0685US9439890B2Triazolone compounds as mPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2015·Granted Sep 13, 2016·4 cites·21 claims
- 0785US7807794B2Anti-α2 integrin antibodies and their usesGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Oct 5, 2010·11 cites·16 claims
- 0884US7842703B2Substituted benzofused derivatives and their use as vanilloid receptor ligandsGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Nov 30, 2010·7 cites·40 claims
- 0984US7205323B2Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparationGLENMARK PHARMACEUTICALS SA·Filed 2005·Granted Apr 17, 2007·8 cites·51 claims
- 1082US10821100B2Triazolone compounds as mPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2019·Granted Nov 3, 2020·1 cites·8 claims
- 1180US9949955B2Triazolone compounds as mPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Apr 24, 2018·2 cites·12 claims
- 1279US7951814B2Quinazolinedione derivatives as TRPA1 modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2009·Granted May 31, 2011·4 cites·23 claims
- 1379US7943634B2Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2005·Granted May 17, 2011·3 cites·15 claims
- 1478US7223789B2Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2004·Granted May 29, 2007·13 cites·77 claims
- 1577US10391083B2Triazolone compounds as MPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2018·Granted Aug 27, 2019·1 cites·14 claims
- 1677US7538128B2Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2007·Granted May 26, 2009·3 cites·47 claims
- 1777US7393846B2Heterocyclic compounds useful for the treatment of inflammatory and allergic disordersGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Jul 1, 2008·3 cites·88 claims
- 1877US7384962B2Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Jun 10, 2008·3 cites·25 claims
- 1974US10213558B2Drug delivery deviceGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Feb 26, 2019·4 cites·20 claims
- 2074US7923465B2Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparationGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Apr 12, 2011·3 cites·40 claims
- 2170US7524844B2Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2007·Granted Apr 28, 2009·1 cites·51 claims
- 2269USD823460SAnal deviceGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Jul 17, 2018·17 cites·1 claims
- 2369US8987278B2Thienopyrimidinedione derivatives as TRPA1 modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Mar 24, 2015·1 cites·29 claims
- 2469US8349846B2Fused pyrimidine derivatives as TRPV3 modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2009·Granted Jan 8, 2013·2 cites·25 claims
- 2569US2020102403A1T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 2665US9682977B2Bicyclic heteroaryl indole analogues useful as ROR gamma modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Jun 20, 2017·1 cites·11 claims
- 2765US9000159B2Fused pyrimidine-dione derivatives as TRPA1 modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Apr 7, 2015·1 cites·16 claims
- 2865US2020024367A1Hetero-Dimeric ImmunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 2963US10336688B2Carbocyclic compounds as ROR gamma modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2018·Granted Jul 2, 2019·0 cites·10 claims
- 3063US2023000872A1Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic painGLENMARK PHARMACEUTICALS SA·Filed 2022·Application pending·0 cites
- 3162US10988467B2Compounds as ROR gamma modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2019·Granted Apr 27, 2021·0 cites·9 claims
- 3262US2014294824A1Antibodies that bind to ox40 and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 3361US2020172634A1Expression Constructs and Methods for Expressing Polypeptides in Eukaryotic CellsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 3461US2020197370A1NANOPARTICULATE FORMULATION COMPRISING AN mPGES-1 INHIBITORGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 3561US2017145115A1Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 3660US2009182143A1Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2008·Application pending·0 cites
- 3759US10457649B2Polymorphs of a mPGES-1 inhibiting triazolone compoundGLENMARK PHARMACEUTICALS SA·Filed 2018·Granted Oct 29, 2019·0 cites·8 claims
- 3859US2018094077A1Hetero-Dimeric ImmunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2017·Application pending·0 cites
- 3959US2020010568A1Purification of hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 4058US2017260280A1Antibodies that Bind to OX40 and Their UsesGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 4158US2018112011A1T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2015·Application pending·0 cites
- 4257US2020079863A1Antibodies that bind to tl1a and their usesGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 4356US2009281146A1Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamideGLENMARK PHARMACEUTICALS SA·Filed 2009·Application pending·0 cites
- 4456US2015056655A1Expression constructs and methods for expressing polypeptides in eukaryotic cellsGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 4555US2019056396A1Expression constructs and methods for selecting host cells expressing polypeptidesGLENMARK PHARMACEUTICALS SA·Filed 2018·Application pending·0 cites
- 4654US10112914B2Polymorphs of a mPGES-1 inhibiting triazolone compoundGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Oct 30, 2018·0 cites·10 claims
- 4754US9073955B22-amino-4-arylthiazole compounds as TRPA1 antagonistsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Jul 7, 2015·0 cites·6 claims
- 4854US8889862B22-amino-4-arylthiazole compounds as TRPA1 antagonistsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Nov 18, 2014·0 cites·6 claims
- 4954US2015183885A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 5054US2014341892A1Anti-alpha2 integrin antibodies and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
Showing the top 50 of 90 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when GLENMARK PHARMACEUTICALS SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →